276 related articles for article (PubMed ID: 24489444)
1. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis.
García-De-Vicuña C; Díaz-Llopis M; Salom D; Bou R; Díaz-Cascajosa J; Cordero-Coma M; Ortega G; Ortego-Centeno N; Suarez-De-Figueroa M; Cruz-Martínez J; Fonollosa A; Blanco R; García-Aparicio ÁM; Benítez-Del-Castillo JM; Antón J
Mediators Inflamm; 2013; 2013():560632. PubMed ID: 24489444
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab for juvenile idiopathic arthritis-associated uveitis.
Magli A; Forte R; Navarro P; Russo G; Orlando F; Latanza L; Alessio M
Graefes Arch Clin Exp Ophthalmol; 2013 Jun; 251(6):1601-6. PubMed ID: 23446556
[TBL] [Abstract][Full Text] [Related]
3. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF
Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series.
La Torre F; Cattalini M; Teruzzi B; Meini A; Moramarco F; Iannone F
BMC Res Notes; 2014 May; 7():316. PubMed ID: 24886032
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
6. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
7. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.
Cecchin V; Zannin ME; Ferrari D; Pontikaki I; Miserocchi E; Paroli MP; Bracaglia C; Marafon DP; Pastore S; Parentin F; Simonini G; De Libero C; Falcini F; Petaccia A; Filocamo G; De Marco R; La Torre F; Guerriero S; Martino S; Comacchio F; Muratore V; Martini G; Vittadello F; Zulian F
J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140
[TBL] [Abstract][Full Text] [Related]
8. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
Ramanan AV; Dick AD; Benton D; Compeyrot-Lacassagne S; Dawoud D; Hardwick B; Hickey H; Hughes D; Jones A; Woo P; Edelsten C; Beresford MW;
Trials; 2014 Jan; 15():14. PubMed ID: 24405833
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
Ramanan AV; Dick AD; Jones AP; McKay A; Williamson PR; Compeyrot-Lacassagne S; Hardwick B; Hickey H; Hughes D; Woo P; Benton D; Edelsten C; Beresford MW;
N Engl J Med; 2017 Apr; 376(17):1637-1646. PubMed ID: 28445659
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study.
Heiligenhaus A; Klotsche J; Tappeiner C; Sengler C; Niewerth M; Liedmann I; Hoeft S; Walscheid K; Lavric M; Foell D; Minden K
Rheumatology (Oxford); 2019 Jun; 58(6):975-986. PubMed ID: 30590748
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
[TBL] [Abstract][Full Text] [Related]
12. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.
Quartier P; Baptiste A; Despert V; Allain-Launay E; Koné-Paut I; Belot A; Kodjikian L; Monnet D; Weber M; Elie C; Bodaghi B;
Ann Rheum Dis; 2018 Jul; 77(7):1003-1011. PubMed ID: 29275333
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases.
Dipasquale V; Atteritano M; Fresta J; Castagna I; Conti G
J Clin Pharm Ther; 2019 Jun; 44(3):482-485. PubMed ID: 30815892
[TBL] [Abstract][Full Text] [Related]
14. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.
Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756
[TBL] [Abstract][Full Text] [Related]
15. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.
Correll CK; Bullock DR; Cafferty RM; Vehe RK
Clin Rheumatol; 2018 Feb; 37(2):549-553. PubMed ID: 29103180
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis.
Marino A; Marelli L; Nucci P; Caporali R; Miserocchi E
Ocul Immunol Inflamm; 2023 Dec; 31(10):1997-2000. PubMed ID: 36657742
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
18. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.
Brunelli JB; Silva CA; Pasoto SG; Saa CGS; Kozu KT; Goldenstein-Schainberg C; Leon EP; Vendramini MBG; Fontoura N; Bonfa E; Aikawa NE
Clin Rheumatol; 2020 Feb; 39(2):515-521. PubMed ID: 31707543
[TBL] [Abstract][Full Text] [Related]
19. Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases.
Yamazaki S; Shimbo A; Akutsu Y; Takase H; Morio T; Mori M
Pediatr Rheumatol Online J; 2020 Mar; 18(1):26. PubMed ID: 32293465
[TBL] [Abstract][Full Text] [Related]
20. Juvenile idiopathic arthritis-associated uveitis.
Sen ES; Ramanan AV
Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):517-534. PubMed ID: 29773271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
